• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Recombinant Proteins Market

    ID: MRFR/LS/19951-CR
    128 Pages
    Rahul Gotadki
    April 2024

    Recombinant Proteins Market Size, Growth Research Report By Product (Hormones, Growth Factors, Antibody, Enzymes and Other Types of Products), By Application (Research Applications, Therapeutic Use, Biotechnology Industry) and By Region (North America, Europe, Asia-Pacific and Rest of The World) –Competitor Industry Analysis and Trends Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Recombinant Proteins Market Research Report — Global Forecast till 2034 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Recombinant Proteins Market Summary

    As per Market Research Future Analysis, the Recombinant Proteins Market was valued at 3.46 USD Billion in 2024 and is projected to reach 7.48 USD Billion by 2034, growing at a CAGR of 8.00% from 2025 to 2034. The market is driven by increased investments in healthcare R&D, rising chronic disease prevalence, and regulatory efforts to reduce viral infections. The antibody segment leads the market, accounting for 58% of revenue, primarily due to the growing incidence of diabetes. The therapeutic use segment also dominates, representing 58% of market revenue, fueled by the demand for effective treatments for chronic conditions like cancer and diabetes.

    Key Market Trends & Highlights

    The Recombinant Proteins Market is experiencing significant growth driven by chronic disease prevalence and R&D investments.

    • In 2022, approximately 1.9 million new cancer cases were diagnosed in the US, with cancer being the second leading cause of death.
    • The antibody segment accounted for 58% of market revenue, driven by rising diabetes cases projected to reach 783 million by 2045.
    • The therapeutic use segment also represented 58% of market revenue, highlighting the demand for protein therapeutics in chronic disease treatment.
    • North America is expected to lead market growth due to advancements in neurodegenerative disease research and a high number of clinical trials.

    Market Size & Forecast

    2024 Market Size USD 3.46 Billion
    2034 Market Size USD 7.48 Billion
    CAGR (2025-2034) 8.00%

    Major Players

    Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC

    Recombinant Proteins Market Trends

    Rising incidence of chronic diseases and increasing investments in research and development are driving the market growth.

    Market CAGR for Recombinant Proteins is driven by the rising incidence of chronic diseases and increasing investments in research and development. The increasing prevalence of chronic illnesses has fueled the demand for precise and efficient protein-based therapeutic interventions. According to the American Cancer Society, the yearly incidence and mortality rates of cancer, including lung, breast, colorectal, prostate and skin cancers, remain significant. Several factors contribute to cancer risk, such as tobacco consumption, poor dietary habits, sedentary lifestyle, excessive sun exposure and exposure to certain environmental toxins.

    Notably, breast, lung, bronchus, prostate and colorectal cancers collectively represent nearly half of all new cancer cases in the United States, while lung, bronchus, colorectal, pancreatic and breast cancers account for almost half of all cancer-related deaths. In 2022, approximately 1.9 million new cancer cases were diagnosed in the US, resulting in 609,360 deaths. Cancer stands as the second leading cause of death in the country. Furthermore, China recorded an estimated 4,820,000 new cancer cases and 3,210,000 cancer-related deaths in 2022, as per the latest data.

    According to the Indian Council of Medical Research's National Cancer Registry Programme (ICMR-NCRP), cervical cancer cases in India surpassed 340,000 in 2023. India witnessed over 1.41 million new cancer cases and more than 910,000 deaths in 2022, with breast cancer being the most prevalent, according to the World Health Organization (WHO).

    The market growth is bolstered by increasing investments in research and development aimed at introducing novel recombinant protein therapeutics. For example, a May 2022 update from the National Institutes of Health (NIH) in the United States revealed that approximately USD 1,021 million was allocated for research and development funding for autoimmune diseases in 2021, with projections indicating a further increase to USD 1,061 million in 2022.

    Consequently, this surge in investment is driving the development of recombinant protein-based medications, thus propelling the expansion of the analyzed market. As a result, it is anticipated that throughout the projection period, demand for the Recombinant protein market will increase due to the Rising incidence of chronic diseases and increasing investments in research and development. Thus, driving the Recombinant Proteins Market revenue.

    The ongoing advancements in biotechnology are likely to enhance the production and application of recombinant proteins, potentially revolutionizing therapeutic strategies and diagnostics in the healthcare sector.

    U.S. National Institutes of Health (NIH)

    Recombinant Proteins Market Drivers

    Market Growth Projections

    The Global Recombinant Proteins Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 3.46 USD Billion in 2024, it is expected to reach 8.08 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.01% from 2025 to 2035. This growth is indicative of the increasing reliance on recombinant proteins in various applications, including therapeutics and diagnostics. The market dynamics suggest a robust expansion driven by technological advancements, rising demand for biopharmaceuticals, and increased investment in research and development.

    Advancements in Biotechnology

    Technological advancements in biotechnology significantly influence the Global Recombinant Proteins Market Industry. Innovations in genetic engineering, protein expression systems, and purification techniques enhance the efficiency and yield of recombinant protein production. These advancements facilitate the development of novel therapeutics and diagnostics, thereby expanding the application scope of recombinant proteins. As a result, the industry is poised for substantial growth, with the market expected to reach 3.46 USD Billion in 2024. The continuous evolution of biotechnological methods suggests a promising trajectory for the industry, potentially leading to a market value of 8.08 USD Billion by 2035.

    Regulatory Support and Frameworks

    Regulatory support and frameworks are essential drivers of the Global Recombinant Proteins Market Industry. Governments worldwide are establishing guidelines and policies that facilitate the development and approval of recombinant protein-based therapies. This supportive environment encourages investment and innovation, leading to a more dynamic market landscape. The anticipated growth trajectory, with the market expected to reach 3.46 USD Billion in 2024 and 8.08 USD Billion by 2035, reflects the positive impact of regulatory initiatives on the industry. Such frameworks not only enhance safety and efficacy but also promote public confidence in recombinant protein therapies.

    Rising Demand for Biopharmaceuticals

    The Global Recombinant Proteins Market Industry experiences a notable surge in demand for biopharmaceuticals, driven by the increasing prevalence of chronic diseases and genetic disorders. As healthcare systems evolve, there is a growing emphasis on personalized medicine, which relies heavily on recombinant proteins for therapeutic applications. This trend is reflected in the market's projected growth, with an estimated value of 3.46 USD Billion in 2024 and a forecasted increase to 8.08 USD Billion by 2035. The compound annual growth rate (CAGR) of 8.01% from 2025 to 2035 underscores the potential for recombinant proteins to play a pivotal role in future healthcare solutions.

    Growing Awareness of Genetic Disorders

    The Global Recombinant Proteins Market Industry is significantly impacted by the growing awareness of genetic disorders among healthcare professionals and patients. As understanding of genetic conditions improves, there is a corresponding increase in the demand for targeted therapies that utilize recombinant proteins. This heightened awareness drives research initiatives and the development of innovative treatments, contributing to the market's expansion. The industry is projected to grow from 3.46 USD Billion in 2024 to 8.08 USD Billion by 2035, indicating a robust response to the rising need for effective therapeutic options for genetic disorders.

    Increased Investment in Research and Development

    Investment in research and development (R&D) plays a crucial role in propelling the Global Recombinant Proteins Market Industry forward. Governments and private entities are increasingly allocating funds to explore the therapeutic potential of recombinant proteins. This influx of capital fosters innovation, enabling the discovery of new applications and enhancing existing products. The commitment to R&D is reflected in the market's anticipated growth, with projections indicating a rise from 3.46 USD Billion in 2024 to 8.08 USD Billion by 2035. Such investments are likely to yield breakthroughs that could redefine treatment paradigms across various medical fields.

    Market Segment Insights

    Recombinant Proteins Market Product Insights

    The Recombinant Proteins Market segmentation, based on Product, includes Hormones, Growth Factors, Antibody, Enzymes and Other Types of Products. The antibody segment dominated the market, accounting for 58% of market revenue. The growth of this segment is fueled by the rising prevalence of diabetes and the expanding use of antibodies. For example, the International Diabetes Federation (IDF) reported in 2021 that ly, there were 537 million cases of diabetes, with projections indicating an increase to 783 million cases by 2045.

    Therefore, the segment's expansion is attributed to the surge in chronic diseases like diabetes, which is driving demand for recombinant antibodies.

    Recombinant Proteins Market Application Insights

    The  Recombinant Proteins Market segmentation, based on the Application, includes Research Application, Therapeutic Use and Biotechnology Industry. The therapeutic use segment dominated the market, accounting for 58% of market revenue. Protein therapeutics provide highly efficient treatments for conditions such as diabetes, cancer, infectious diseases, hemophilia and anemia. The International Diabetes Federation reports that approximately 537 million individuals aged 20-79 had diabetes in 2021. Projections indicate that the  diabetic population will reach 643 million by 2030 and 783 million by 2045.

    With the substantial growth in the diabetic population, the demand for recombinant proteins in the therapeutics segment is expected to experience significant growth in the upcoming years.

    Figure 1:  Recombinant Proteins Market, by Application, 2023 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Get more detailed insights about Recombinant Proteins Market Research Report — Global Forecast till 2034

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The anticipated expansion of the Recombinant Proteins market in North America can be attributed to several key factors. Progressive research aimed at treating various neurodegenerative conditions such as Alzheimer's disease and dementia is contributing to the expansion of the analyzed market. Considerable time and resources in Alzheimer's research have been allocated to studying a protein known as amyloid, as many researchers in the field believe that targeting amyloid is pivotal in addressing the root cause of the disease.

    This focus on amyloid is anticipated to drive the demand for therapies targeting this protein.

    For instance, an article published in the journal ANC in April 2022 highlighted the significance of plaque-associated proteins in understanding amyloid plaque development, offering potential biomarkers or therapeutic targets for Alzheimer's disease. Additionally, the growing number of clinical trials conducted in the country is boosting demand for the analyzed market. For instance, in 2022, Clinicaltrials.gov reported approximately 15,316 registered clinical trials in the United States involving biopharmaceuticals. This uptrend in clinical trial activity is expected to fuel market growth in the country.

    Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil.

    Figure 2:  RECOMBINANT PROTEINS MARKET SHARE BY REGION 2023 (USD Billion)

    RECOMBINANT PROTEINS MARKET SHARE BY REGION 2023

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe's Recombinant Proteins Market accounts for the second-largest market share as Advancements in recombinant DNA technology, cell culture methodologies, protein expression systems and increased accessibility to high-yield expression systems such as mammalian cell lines, yeast and bacteria all contribute to driving growth in the Recombinant Proteins Market. Europe hosts several countries renowned for their high focus on research and development (R&D), including the UK, Germany and Denmark.

    For instance, according to EuroDev, the pharmaceutical industry in Germany allocates over USD 6.74 billion (EUR 6.2 billion) annually to R&D and conducted approximately 499 clinical trials funded by research-based pharmaceutical companies in 2019. Further, the German Recombinant Proteins Market held the largest market share and the UK Recombinant Proteins Market was the fastest-growing market in the European region.

    The Asia-Pacific Recombinant Proteins Market is expected to grow at the fastest CAGR from 2025 to 2034. The Asia Pacific region is experiencing expansion driven by an upsurge in both public and private funding for research and development in recombinant protein studies, favorable government regulations and the increasing prevalence of target diseases among an aging population.

    In Asia and the Pacific, the number of older individuals is expected to more than double from 630 million in 2020 to approximately 1.3 billion by 2050. In 2020, 13.6% of the population in Asia and the Pacific was aged 60 years or older and by 2050, this demographic is projected to represent one-quarter of the population. Moreover, advancements in proteomic and genomic research techniques are driving growth in the region. Moreover, China’s Recombinant Proteins Market held the largest market share and the Indian Recombinant Proteins Market was the fastest-growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development to expand their product lines, which will help the Recombinant Proteins market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Recombinant Proteins industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Recombinant protein industry to benefit clients and increase the market sector. In recent years, the Recombinant Proteins industry has offered some of the most significant advantages to the fields of medicine, biotechnology and pharmaceuticals. Major players in the Recombinant Proteins Market, including Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC are attempting to increase market demand by investing in research and development operations.

    Merck KGaA, a subsidiary of E. Merck KG, operates as a science and technology company. Its activities encompass the discovery, development and manufacturing of prescription drugs targeting cancer, multiple sclerosis and infertility. Additionally, Merck is involved in the development of various materials, such as liquid crystal mixtures and organic light-emitting diode (OLED) materials, as well as cosmetic active ingredients and pigments for coatings.

    Moreover, the company offers a diverse range of products, including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, along with test assays, analytical reagents and flow cytometry kits and instruments, providing comprehensive solutions across various sectors including healthcare, performance materials and life sciences. With a  presence spanning Europe, North America, Asia-Pacific, Latin America and the Middle East and Africa, Merck is headquartered in Darmstadt, Hesse, Germany. In February 2020, Merck KGaA (Germany) collaborated with Donghao Lansheng (Group) Co., Ltd. on a project based in China.

    This partnership aimed to evaluate a new import policy in China, which is intended to streamline the clearance process for research items used in biomedical innovation and analytical purposes via customs, facilitating Merck's operations in the country.

    Thermo Fisher Scientific Inc. (Thermo Fisher) is a leading provider of medical equipment, analytical instruments, reagents, consumables, software and services designed to address complex analytical challenges across various fields, including research, diagnostics and clinical laboratories. The company offers comprehensive solutions for cellular analysis, biology, flow cytometry and synthetic biology. Its product portfolio encompasses technologies for mass spectrometry, genetic sequencing, electron microscopy, as well as protein and molecular biology research.

    Thermo Fisher serves a diverse customer base, including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic laboratories, government agencies and sectors focusing on environmental, industrial quality and process control. Its products and services are distributed through a variety of channels, including direct sales force, e-commerce platforms and third-party distributors across the Americas, Asia-Pacific and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher continues to expand its  presence.

    In May 2023, Thermo Fisher Scientific Inc. (USA) and the National Research and Innovation Agency of Indonesia (BRIN) entered into a Memorandum of Understanding (MOU) aimed at facilitating and enhancing Indonesia's national research and innovation infrastructure and capabilities.

    Key Companies in the Recombinant Proteins Market market include

    Industry Developments

    July 2023: Dyadic International, Inc. provided an update on its Phase 1 Clinical Trial for the DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. The Data Safety Monitoring Board (DSMB) conducted an interim analysis of Day 29 data for both low and high-dose groups, confirming the absence of significant vaccine-related safety concerns.

    April 2019: Elpiscience BioPharma collaborated with Bio-Techne Corp. (U.S.) and Bio-Techne Corp. (China). Through this partnership, Elpiscience gained access to Bio-Techne's extensive range of recombinant antibodies for the development of preclinical, clinical and commercial biopharmaceuticals aimed at creating anticancer treatments.

    September 2024: ScaleReady and Bio-Techne Corporation developed G-Rex optimized ProPakTM GMP cytokines that increase the productivity of the automated closed system for cell and gene engineering therapy manufacturing

    March 2024: In a recent announcement, Proteintech revealed the opening of the laboratory and office space of its sophisticated new building in the UK. The company has placed research and development, production, logistics and administration under one roof with the new facility so that everything is in one building instead of many small, orderly-spaced offices. All these functions have more than tripled the area of the previous facility.

    In January 2023, the acquisition of PeproTech by Thermo Fisher Scientific Inc. was completed, and now the company possesses another strategic business unit. The business will serve as a strategic fit for the overall company enabling pharma and biotech customers to be served more effectively and proficiently for broader enhancing of their existing capability portfolio

    Recombinant Proteins 

    Future Outlook

    Recombinant Proteins Market Future Outlook

    The global Recombinant Proteins Market is projected to grow at 8.01% CAGR from 2024 to 2035, driven by advancements in biotechnology, increasing demand for therapeutic proteins, and rising investments in research and development.

    New opportunities lie in:

    • Develop novel recombinant proteins for targeted therapies in oncology and rare diseases.
    • Invest in biomanufacturing technologies to enhance production efficiency and reduce costs.
    • Expand into emerging markets with tailored recombinant protein solutions for local healthcare needs.

    By 2035, the Recombinant Proteins Market is expected to achieve substantial growth, reflecting robust innovation and strategic investments.

    Market Segmentation

    Regional Outlook

    • US
    • Canada

    Recombinant Proteins Market Product Outlook

    • Hormones
    • Growth Factors
    • Antibody
    • Enzymes
    • Other Types of Products

    Recombinant Proteins Market Regional Outlook

    • US
    • Canada

    Recombinant Proteins Market Application Outlook

    • Research Applications
    • Therapeutic Use
    • Biotechnology Industry

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    3.46 (USD Billion)
    Market Size 2025    3.74 (USD Billion)
    Market Size 2034    7.48 (USD Billion)
    Compound Annual Growth Rate (CAGR)    8.00 % (2025 - 2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors and Trends
    Segments Covered Product, Application and Region
    Geographies Covered North America, Europe, Asia Pacific and the Rest of the World
    Countries Covered The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil
    Key Companies Profiled Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC
    Key Market Opportunities ·         Increasing focus on research and development
    Key Market Dynamics ·         Surge in chronic disease and chronic disease-related mortalities worldwide

    FAQs

    How much is the Recombinant Proteins Market?

    The Recombinant Proteins Market size was valued at USD 2.97 Billion in 2023.

    What is the growth rate of the Recombinant Proteins Market?

    The Recombinant protein market is projected to grow at a CAGR of 8.00% during the forecast period, 2025-2034.

    Which region held the largest market share in the Recombinant Proteins Market?

    North America had the largest share of the market.

    Who are the key players in the Recombinant Proteins Market?

    The key players in the market are Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC.

    Which Product led the Recombinant Proteins Market?

    The Antibody segment dominated the market in 2023.

    Which Application had the largest market share in the Recombinant Proteins Market?

    The Therapeutic Use segment had the largest share in the market.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials